Results 111 to 120 of about 24,974 (144)

Factores de riesgo dietético para la presencia de Dislipidemias en Escolares [PDF]

, 2013
Benítez Arciniega, Alejandra Donaji, García Abarca, Annarzhvaelig   +1 more
core  

Aspectos fundamentales en la solicitud y determinación de la lipoproteína(a) en el laboratorio clínico. [PDF]

Adv Lab Med
Arrobas Velilla T, Fernández Prendes C, Amigó Grau N, Calmarza P, Camós Anguila S, Candas Estébanez B, Castro Castro MJ, Ceacero D, González Martínez I, Martín Palencia M, Puzo Foncillas J, Romero Román C, en nombre de la Comisión de Lipoproteínas y Enfermedades Cardiovasculares de la SEQCML.   +12 more
europepmc   +1 more source

Antiinflammatory and Cardioprotective Effects of HDL-C: Association With Autoantibodies Against Oxidized LDL? [PDF]

Arq Bras Cardiol, 2022
Figueiredo EL, Wang R.
europepmc   +1 more source

Comment on the firsts insights of the arterial hypertension study in México (RIHTA): are we doing things right? [PDF]

Arch Cardiol Mex
Aguilar-López R, Rojas-Velasco G, Toledo-Elías R.   +2 more
europepmc   +1 more source

Factores Protectores de Enfermedad Cardiovascular [PDF]

, 1998
Fiol Sala, Miguel, Forteza-Rey Borraleras, José, Fullana, Maria   +2 more
core  

[Beyond the plaque: immunological implications of risk factors in atherosclerosis]. [PDF]

Arch Cardiol Mex
Aguilar-Villegas ÓR, Barragán-Los Santos J, Del Moral-Wong LE, Amezcua-Guerra LM, Aguirre-García MM.   +4 more
europepmc   +1 more source

[The dramatic loss of statistical power when dichotomising continuous variables]. [PDF]

Rev Neurol
Carazo-Díaz C, Prieto-Valiente L.
europepmc   +1 more source

Efeitos do volume e da intensidade de exercício aeróbio nas concentrações plasmáticas das lipoproteínas de alta densidade (HDL-C) e lipoproteínas de baixa densidade (LDL-C)

Revista Brasileira de Prescrição e Fisiologia do Exercício, 2011
Elise Burmeister Tirelli
doaj  

From Atheroma to Atherogenic Index, Secular Evidence. [PDF]

Arq Bras Cardiol
Precoma DB, Rocha GLD.
europepmc   +1 more source

[Effectiveness of the CNIC polypill in secondary cardiovascular prevention in the subgroup of patients of the NEPTUNO study using atorvastatin doses of 20 mg]. [PDF]

Arch Cardiol Mex
González-Juanatey JR, Cordero A, Masana L, Dalmau R.   +3 more
europepmc   +1 more source